While the use of ICIs in CRC is mainly limited to patients who are dMMR/MSI, ICIs are sometimes used as later-line therapy in MMR-proficient/MSS patients who have high PD-L1 and TMB scores. Here, CD274 is linked to colorectal carcinoma.